Bo H. Chao

1.8k citations
49 papers · 1.3k indexed · 1 hit paper · h-index 17

Bo H. Chao

47 papers receiving 1.3k citations

Hit Papers

Alectinib in ALK-positive, crizotinib-resistant, non-smal...4622015202620182022100200300400

Peers

Bo H. Chao
Comparison fields: 5 of 95
  • Oncology 872
  • Pulmonary and Respiratory Medicine 833
  • Cancer Research 205
  • Immunology 132
  • Molecular Biology 375
Replace Jeremy Cetnar with:
Jeremy Cetnar United States
Matt D. Galsky United States
Javier Puente Spain
Satoru Kitazono Japan
Gregory Friberg United States
Kenji Tomizawa Japan
Georgy M. Manikhas Russia
Dora Hatzidaki Greece
Pooja Ghatalia United States
Caicun Zhou China
Bo H. Chao relative to Jeremy Cetnar United States Jeremy Cetnar's profile →
Citations per field
00.5×1.5×
Jeremy Cetnar · 1×
Citations per year

Countries citing papers authored by Bo H. Chao

Since Specialization
Citations

This map shows the geographic impact of Bo H. Chao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bo H. Chao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bo H. Chao more than expected).

Fields of papers citing papers by Bo H. Chao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bo H. Chao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bo H. Chao. The network helps show where Bo H. Chao may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Bo H. Chao, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Bo H. Chao Line = papers co-authored together Bo H. Chao links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20250
2 20252
3 20233
4 20233
5 20214
6 202110
7 202031
8 202036
9 202044
10 202019
11 2018114
12 20182
13 201710
14 201614
15 201655
16
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trialbreakdown →
2015462
17 201010
18 20099
19 200712
20 200443

About Bo H. Chao

Bo H. Chao is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research, having authored 49 papers that have together received 1.3k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (23 papers), Lung Cancer Diagnosis and Treatment (11 papers), Cancer Genomics and Diagnostics (10 papers), Cancer Immunotherapy and Biomarkers (8 papers), Colorectal Cancer Treatments and Studies (7 papers), Lung Cancer Research Studies (4 papers), Ubiquitin and proteasome pathways (3 papers) and Renal cell carcinoma treatment (2 papers). The work is most often cited by research in Oncology (872 citations), Pulmonary and Respiratory Medicine (833 citations) and Cancer Research (205 citations). Bo H. Chao has collaborated with scholars based in United States, France and China. Frequent co-authors include Leena Gandhi, Mark A. Socinski, Sai‐Hong Ignatius Ou, D. Ross Camidge, Hossein Borghaei, Shirish M. Gadgeel, Bogdana Balas, Alberto Chiappori, Tarek Mekhail and Gregory J. Riely.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026